At Cellinfinity, we believe cells have infinite potential to cure human diseases. We have used our proprietary directed evolution platform to identify set of gene modifications that substantially improve CAR-T and CAR-NK cells to cure solid tumors. Our directed evolution process involves site-specific knock-in of CRISPR guide library and allows whole genome gain-of-function or loss-of-function evaluation. Following selection of engineered cells with desired properties (e.g. potency, proliferation, infiltration and in vivo activity against solid tumors) we identified set of unique gene modifications in CAR-Ts and CAR-NKs that substantially augment anti-tumor activity. We have used this technology to develop first-in-class and/or best-in-class portfolio products (CAR-Ts and CAR-NKs) armored with specific gene enhancements against solid tumors.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2021
Main Therapeutic Focus:
Oncology
Lead Product in Development:
CAR-T against solid tumors
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
